Publications

When we look back at the close of the 21st century’s first decade, we are likely to view the global financial crisis as the final blow that pushed the pharmaceutical industry into a period of upheaval. Human resources executives are being asked to design talent strategies as the business playbook changes daily.

As the generics pharmaceuticals business model evolves, the industry faces many of the same challenges as those of the traditional big pharma. Consequently, generic drug companies may find that the key to continued growth will be breaking with tradition and recruiting and retaining seasoned big pharma executives. But, it cuts both ways, and big pharma may find that the expertise of generic drug executives accustomed to leaner budgets and product cycles is the tonic they need.

India's pharmaceutical industry is experiencing tremendous growth and is poised for even more success. In order to grow and truly compete with Big Pharma, however, these companies will need to think strategically about their resources, both human and financial.

The growth rate of most MNCs in China is, by any standard, phenomenal. What are the implications?